GLP-1 FOIA Monitor
594 FOIA Requests Track the GLP-1 Class
This tracker pulls every closed and open FDA FOIA request referencing semaglutide, tirzepatide, liraglutide, dulaglutide, exenatide, lixisenatide, or orforglipron — across all doc types, from adverse-event data pulls to approval packages to internal FDA correspondence.
By Molecule
| Drug / Brands | All-Time | Pending | 2026 YTD |
|---|---|---|---|
|
Semaglutide Ozempic / Wegovy / Rybelsus |
355 | 49 | 55 |
|
Tirzepatide Mounjaro / Zepbound |
189 | 25 | 31 |
|
Liraglutide Victoza / Saxenda |
74 | 11 | 20 |
|
Dulaglutide Trulicity |
21 | 3 | 10 |
|
Exenatide Byetta / Bydureon |
12 | 2 | 2 |
|
Orforglipron Foundayo (oral, pending approval) |
11 | 5 | 8 |
|
Lixisenatide Adlyxin |
3 | 0 | 2 |
Requests by Year
Currently Pending — Oldest First
Showing 25 of 80 pending requests, sorted by how long they've been open. Rows shaded gold are 1+ years open; red are 2+ years.
Withdrawn Requests
Withdrawals are usually FDA closing a request as a duplicate of an existing one, or the requester narrowing scope after an initial broad filing. A late-2025 wave of Washington Post filings on GLP-1 intestinal-obstruction safety signals (labeling, FAERS, correspondence) were withdrawn in this pattern — worth noting since White Mountain Films is currently running a nearly identical set of pending requests on the same ileus/obstruction signal (EIR, label, and correspondence records for Novo Nordisk's Plainsboro, NJ site), suggesting overlapping investigative interest in that safety signal from two different requesters.
Requester Landscape
Roughly a quarter of GLP-1 FOIA volume comes from press (gastrointestinal safety signals, compounding pharmacy coverage, shortage reporting). Plaintiff-side law firms — led by Morgan & Morgan, active in GLP-1 injury litigation — make up another large share, largely pulling FAERS adverse-event data and approval packages for discovery. One requester, FOIA Professional Services, has filed 81 near-identical FAERS pulls across a wide drug list including GLP-1s — consistent with a data-resale operation rather than a single case or story.
Top Individual Requesters
Latest Closures
What's Being Requested
FAERS (adverse event) pulls dominate the GLP-1 request mix — a signal of ongoing safety-monitoring interest from press, plaintiff firms, and data resellers alike, well ahead of approval-package requests (NDA/ANDA/BLA).